CD19 and neoplasm: Our study indicated that h1218-CART19 cells showed a reduced activation response when stimulated by CD19, and they demonstrated improved in vivo proliferation and tumor control ability in xenograft mouse models of B-cell acute leukemia compared with FMC63-CART19 cells.